Eli Lilly and Company (LLY)
| Market Cap | 900.85B +8.8% |
| Revenue (ttm) | 65.18B +44.7% |
| Net Income | 20.64B +94.9% |
| EPS | 22.95 +96.0% |
| Shares Out | 893.36M |
| PE Ratio | 43.94 |
| Forward PE | 29.09 |
| Dividend | $6.92 (0.69%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 2,801,737 |
| Open | 986.89 |
| Previous Close | 990.33 |
| Day's Range | 980.58 - 1,008.93 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 1,174.53 (+16.48%) |
| Earnings Date | Feb 4, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,174.53, which is an increase of 16.48% from the latest price.
News
Virtus Large Cap Growth SMA Q4 2025 Portfolio Review
The Silvant Large Cap Growth SMA returned +2.69% (gross)/+1.94% (net) for the quarter, outperforming the Russell 1000 Growth Index's return of +1.12%. Eli Lilly and Alphabet were among the top stock c...
Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs
Eli Lilly said on Monday a small number of basic Medicare drug plans may not follow the $50 per month cap on out-of-pocket costs for its weight-loss drugs, under the Medicare agency's weight-loss dr...
Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies
U.S. considers global AI chip export restrictions, impacting Nvidia and AMD as shares fall on regulatory risk. A 30-day U.S. waiver allows India to purchase stranded Russian crude, aiming to stabilize...
What Are The Biggest Risks To Eli Lilly Stock?
Eli Lilly stock (LLY) is currently trading near $1,000, reflecting a decline of over 11% from its 52-week high as investors recalibrate expectations against emerging headwinds.
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. The "Employer Connect" platform gives employers mor...
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
Zepbound® (tirzepatide) KwikPen® for single-patient use available from Lilly at $449 across all doses through the Lilly Employer Connect platform, with reduced cost-share pricing available to employee...
GLP-1 drugs protect against new or worsening addictions, large study shows
Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance use disorders and alleviate existing addictions, according to findings from a large study of U.S. milit...
Baron Health Care Fund Q4 2025 Contributors And Detractors
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the com...
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
Eli Lilly CFO Lucas Montarce said on Monday it is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as the second quarter of this year, once it gets a...
Why Eli Lilly is Winning the Weight Loss War
WSJ's David Wainer breaks down why Novo Nordisk struggled and Eli Lilly prospered in the weight loss drug market. #
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is t...
Eli Lilly reports additional data on weight-loss pill from diabetes trial
Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, orforglipron, and rival Novo Nordisk's oral semaglutide in diabetes patients, giving a more deta...
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3 In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) ...
Columbia Balanced Fund Q4 2025 Contributors And Detractors
Lilly delivered exceptional performance over the period, driven by sustained strength in its diabetes and obesity portfolio. Applied Materials outperformed during the quarter, as AI-driven wafer-fab i...
Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan
Shares of Novo Nordisk and rival Eli Lilly fell on Tuesday after a report said price cuts are coming for the popular weight-loss drugs.
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for the Dani...
Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen
The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or the multi-dose pen that delivers four weekly injections from a single device...
Novo Nordisk's Loss Is Eli Lilly's Gain
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro bra...
Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push
Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart: a new injector pen, a new box, another reminder to refill, and one more item for the sharps bin. Eli Lilly is trying to ...
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some patien...
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound® Zepbound patients can access all doses in either multi-dose KwikPen...
Novo Nordisk Stock Plunges and Eli Lilly Jumps. It's All Down to This Weight-Loss Drug Trial.
Novo shares slump after the Danish drugmaker's experimental obesity drug fails to beat Lilly's treatment in an 84-week trial.
These Stocks Are Today's Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More
Nvidia shares tick up as investors await the chip maker's fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.